Glucagon as a Critical Factor in the Pathology of Diabetes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
tudies from the laboratory of Roger Unger presented in the current issue of Diabetes highlight the potential benefit of reducing glucagon action by examining the effects of glucagon receptor knockout (Gcgr 2/2 ) on the phenotype of type 1 diabetes in the mouse (1).The aim of the study was to determine if glucagon action, by itself, causes the lethal consequences of insulin deficiency.Because treatment of Gcgr 2/2 mice with the b-cell toxin streptozotocin (STZ) previously had no effect on circulating insulin levels or pancreatic islet architecture (2), Lee et al. (1) administered a double dose of STZ to maximize b-cell destruction.Unlike STZ treated wild-type Gcgr +/+ mice, which became severely hyperglycemic, STZ-treated mice lacking glucagon signaling appeared to be in a normal state of health and were completely protected from the manifestations of diabetes (1), as shown previously by the same group in alloxan treated Gcgr 2/2 mice (3) and by Hancock et al. (4) in STZtreated mice lacking glucagon because of a-cell deletion.Fasting hyperglycemia did not occur in STZ-treated Gcgr 2/2 mice, and astonishingly, the animals demonstrated normal or even improved glucose disposal in response to a glucose tolerance test, despite the absence of a rise in plasma insulin.These results led the authors to speculate that insulin action during glucose absorption is largely directed toward overcoming the hepatic actions of glucagon.They theorized that insulin would have little or no role in a liver not exposed to the action of glucagon because it would be in a permanent glucose storage mode.Glucagon antagonistic peptides, neutralizing antibodies, receptor antisense oligonucleotides, and/or receptor nonpeptidyl antagonists have previously been shown to lower plasma glucose in several rodent models of diabetes (5,6).Likewise, reversal of diabetes by leptin therapy in the rodent has been attributed to a reduction in plasma glucagon (3,7), although other actions of leptin could not be ruled out.Reduction of glucagon in pancreatectomized canines caused a marked decrease in hepatic glucose production (8) and suppression of glucagon in diabetic humans improved glucose tolerance (9,10).Thus, there is strong evidence supporting a role for glucagon in contributing to diabetic hyperglycemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zisman, A., Peroni, O. D., Abel, E. D., Michael, M. D., Mauvais-Jarvis, F., Lowell, B. B., Wojtaszewski, J. F. P., Hirshman, M. F., Virkamaki, A., Goodyear, L. J., et al. (2000) · Nature Medicine · doi:10.1038/78693 · Cited by 743 · cited 2×
“Likewise, compensatory insulin-independent muscle glucose transport appeared to occur in whole body GLUT4null mice (26).”
BackgroundWasserman, D. H. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90563.2008 · Cited by 384 · cited 1×
“Instead, insulin is the primary regulator, acting to rapidly increase muscle blood flow, stimulate transmembrane glucose transport, and activate muscle glycogen synthase (22).”
BackgroundDunning, B. E., & Gerich, J. E. (2007) · Endocrine Reviews · doi:10.1210/er.2006-0026 · Cited by 369
Shah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368
Boden, G. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-39781 · Cited by 348 · cited 1×
“In any event, NEFAs have been shown to inhibit hepatic and muscle glucose uptake (30).”
BackgroundGlucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 9×
“Unlike STZ treated wild-type Gcgr mice, which became severely hyperglycemic, STZ-treated mice lacking glucagon signaling appeared to be in a normal state of health and were completely protected from the manifestations of diabetes (1), as shown previously by the same group in alloxan treated Gcgr mice (3) and by Hancoc…”
BackgroundInfluentialThe Glucagon Receptor Is Required for the Adaptive Metabolic Response to Fasting
Longuet, C., Sinclair, E. M., Maida, A., Baggio, L. L., Maziarz, M., Charron, M. J., & Drucker, D. J. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.09.008 · Cited by 272
Conarello, S. L., Jiang, G., Mu, J., Li, Z., Woods, J., Zycband, E., Ronan, J., Liu, F., Roy, R. S., Zhu, L., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0481-3 · Cited by 224
Making insulin-deficient type 1 diabetic rodents thrive without insulin
Yu, X., Park, B.-H., Wang, M.-Y., Wang, Z. V., & Unger, R. H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806993105 · Cited by 219
Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190 · cited 1×
“Reduction of glucagon in pancreatectomized canines caused a marked decrease in hepatic glucose production (8) and suppression of glucagon in diabetic humans improved glucose tolerance (9,10).”
Background
Cited by
Animal models of obesity and diabetes mellitus
Kleinert, M., Clemmensen, C., Hofmann, S. M., Moore, M. C., Renner, S., Woods, S. C., Huypens, P., Beckers, J., de Angelis, M. H., Schürmann, A., et al. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.161 · Cited by 832
Self-citationGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670
Self-citationThe New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“In summary, there is appreciable evidence indicating that glucagon is associated in the pathology of diabetes and that inhibition of glucagon signaling can improve glycemic control (13, 165, 169).”
BackgroundPhysiologic action of glucagon on liver glucose metabolism
Ramnanan, C. J., Edgerton, D. S., Kraft, G., & Cherrington, A. D. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01454.x · Cited by 293
Reversal of Type 1 Diabetes in Mice by Brown Adipose Tissue Transplant
Gunawardana, S. C., & Piston, D. W. (2012) · Diabetes · doi:10.2337/db11-0510 · Cited by 290
Metadata
- Authors
- Edgerton, D. S., & Cherrington, A. D.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-01-21
- Volume
- 60
- Issue
- 2
- Pages
- 377-380
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2146519855
- Cited by
- 47
- References
- 10
- FWCI
- 5.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.